The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/ Emtricitabine-containing HAART Regimens
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) has been the first choice nucleoside reverse transcriptase inhibitor (NRTI) according to many reliable antiretroviral treatment (ART) guidelines because of its high efficacy. However, TDF-related renal toxicity reported in Western countries is a challenging issue regarding clinical use. We conducted this study to evaluate the incidence and characteristics of an acute increase in serum creatinine (Cr) level > 1.5 mg/dL among TDF/FTCbased highly active antiretroviral treatment (HAART)-treated patients. Materials and Methods: We retrospectively reviewed the medical records of 205 HIV-infected patients treated with TDF/FTC-containing regimens between 1 February 2010 and 30 April 2014. Three groups of TDF/FTC + ritonavir-boosted protease inhibitor (PI/ r), TDF/FTC + non-nucleoside reverse transcriptase inhibitor (NNRTI), and TDF/FTC + integrase strand transfer inhibitor (INSTI), and three PI/r subgroups of TDF/FTC + lopinavir (LPV)/r, TDF/FTC + atazanavir (ATV)/r, TDF/FTC + darunavir (DRV)/r were evaluated. Results: A total 136 patients (91 in the TDF/FTC + PI/r group, 20 in the TDF/FTC + NNRTI group and 25 in the TDF/FTC + INSTI group) were included in the statistical analysis. Four cases (4.9%; all in the TDF/FTC + PI/r group) among 136 patients showed an acute increase in serum Cr more than 1.5 mg/dL, so the overall incidence was 2.8 cases per 100 patient-years. One case was a patient treated with TDF/FTC + LPV/r, and the others were treated with TDF/FTC + ATV/r. No case of an acute increase in serum Cr was observed in the TDF/FTC + DRV/r group. The incidence of serum Cr increase more than 1.5 mg/dL in TDF/FTC + PI/r group was 4.0 cases per 100 patient-years. Conclusion: Although only a small number of patients were evaluated retrospectively from a single center, the TDF/FTC + PI/r regimen may have been related with relatively higher tendency of increment of serum Cr level. These findings reinforce the importance of close follow-ups of HIV-infected patients treated with the TDF/FTC + PI/r regimens.
Abstract
Background: The combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) has been the first choice nucleoside reverse transcriptase inhibitor (NRTI) according to many reliable antiretroviral treatment (ART) guidelines because of its high efficacy. However, TDF-related renal toxicity reported in Western countries is a challenging issue regarding clinical use. We conducted this study to evaluate the incidence and characteristics of an acute increase in serum creatinine (Cr) level > 1.5 mg/dL among TDF/FTCbased highly active antiretroviral treatment (HAART)-treated patients. Materials and Methods: We retrospectively reviewed the medical records of 205 HIV-infected patients treated with TDF/FTC-containing regimens between 1 February 2010 and 30 April 2014. Three groups of TDF/FTC + ritonavir-boosted protease inhibitor (PI/ r), TDF/FTC + non-nucleoside reverse transcriptase inhibitor (NNRTI), and TDF/FTC + integrase strand transfer inhibitor (INSTI), and three PI/r subgroups of TDF/FTC + lopinavir (LPV)/r, TDF/FTC + atazanavir (ATV)/r, TDF/FTC + darunavir (DRV)/r were evaluated. Results: A total 136 patients (91 in the TDF/FTC + PI/r group, 20 in the TDF/FTC + NNRTI group and 25 in the TDF/FTC + INSTI group) were included in the statistical analysis. Four cases (4.9%; all in the TDF/FTC + PI/r group) among 136 patients showed an acute increase in serum Cr more than 1.5 mg/dL, so the overall incidence was 2.8 cases per 100 patient-years. One case was a patient treated with TDF/FTC + LPV/r, and the others were treated with TDF/FTC + ATV/r. No case of an acute increase in serum Cr was observed in the TDF/FTC + DRV/r group. The incidence of serum Cr increase more than 1.5 mg/dL in TDF/FTC + PI/r group was 4.0 cases per 100 patient-years. Conclusion: Although only a small number of patients were evaluated retrospectively from a single center, the TDF/FTC + PI/r regimen may have been related with relatively higher tendency of increment of serum Cr level. These findings reinforce the importance of close follow-ups of HIV-infected patients treated with the TDF/FTC + PI/r regimens.
참고문헌 (25)
- "Drug approval package: VIREAD (tenofovir disoproxil fumarate) tablets"[URL]
- "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents"[URL]
- Günthard HF, "Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel", JAMA, 312, pp.410~425 (2014)
- Cooper RD, "Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected ptients", Clin Infect Dis, 51, pp.496~505 (2010)
- Röling J, "HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy", Clin Infect Dis, 42, pp.1488~1495 (2006)
- Choi A, "Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons", Am J Kidney Dis, 56, pp.872~882 (2010)
- Choi AI, "Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons", Circulation, 121, pp.651~658 (2010)
- Quinn KJ, "Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate", Int J STD AIDS, 21, pp.150~151 (2010)
- Nelson MR, "The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years", AIDS, 21, pp.1273~1281 (2007)
- Sax PE, "Renal safety of tenofovir disoproxil fumarate", AIDS Read, 17, pp.90~104 (2007)
- Créput C, "Renal lesions in HIV-1-positive patient treated with tenofovir", AIDS, 17, pp.935~937 (2003)
- Rollot F, "Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine", Clin Infect Dis, 37, pp.e174~e176 (2003)
- Wood SM, "Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males", AIDS Patient Care STDS, 23, pp.1~4 (2009)
- Goicoechea M, "Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy", J Infect Dis, 197, pp.102~108 (2008)
- Young J, "Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir", AIDS, 26, pp.567~575 (2012)
- Horberg M, "Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients", J Acquir Immune Defic Syndr, 53, pp.62~69 (2010)
- Scherzer R, "Association of tenofovir exposure with kidney disease risk in HIV infection", AIDS, 26, pp.867~875 (2012)
- Calza L, "Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients", Scand J Infect Dis, 43, pp.656~660 (2011)
- Kohler JJ, "Tenofovir renal toxicity targets mitochondria of renal proximal tubules", Lab Invest, 89, pp.513~519 (2009)
- Puls RL, "Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study", Clin Infect Dis, 51, pp.855~864 (2010)
- Ryom L, "Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study", J Infect Dis, 207, pp.1359~1369 (2013)
- Sax PE, "Abacavir", lamivudine versus tenofovir DF, J Infect Dis, pp.2011, 204[DOI]
- "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents"[URL]
- Hall AM, "Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence", Am J Kidney Dis, 57, pp.773~780 (2011)
- Gallant JE, "Renal function with use of a tenofovir-containing initial antiretroviral regimen", AIDS, 23, pp.1971~1975 (2009)